Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alzamend Neuro, Inc. stock logo
ALZN
Alzamend Neuro
$3.90
-1.8%
$5.75
$3.06
$135.54
$3.13M-0.28428,939 shs216,505 shs
Nutra Pharma Corp. stock logo
NPHC
Nutra Pharma
$0.00
$0.00
$0.00
$710K-0.21127,366 shsN/A
Spruce Biosciences, Inc. stock logo
SPRB
Spruce Biosciences
$0.07
+9.0%
$0.14
$0.06
$0.73
$2.77M2.38720,009 shs23,724 shs
Windtree Therapeutics, Inc. stock logo
WINT
Windtree Therapeutics
$0.65
-2.3%
$1.03
$0.64
$737.44
$2.39M0.77762,113 shs198,924 shs
Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alzamend Neuro, Inc. stock logo
ALZN
Alzamend Neuro
+3.66%+19.58%-35.13%-38.73%-92.39%
Nutra Pharma Corp. stock logo
NPHC
Nutra Pharma
0.00%0.00%0.00%-50.00%0.00%
Spruce Biosciences, Inc. stock logo
SPRB
Spruce Biosciences
-7.38%-5.94%-16.27%-83.25%-91.36%
Windtree Therapeutics, Inc. stock logo
WINT
Windtree Therapeutics
-15.80%-20.81%-34.78%-67.39%-99.60%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Alzamend Neuro, Inc. stock logo
ALZN
Alzamend Neuro
3.3242 of 5 stars
3.54.00.00.02.94.20.0
Nutra Pharma Corp. stock logo
NPHC
Nutra Pharma
N/AN/AN/AN/AN/AN/AN/AN/A
Spruce Biosciences, Inc. stock logo
SPRB
Spruce Biosciences
2.3855 of 5 stars
3.05.00.00.00.01.71.3
Windtree Therapeutics, Inc. stock logo
WINT
Windtree Therapeutics
1.4477 of 5 stars
3.02.00.00.01.10.01.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Alzamend Neuro, Inc. stock logo
ALZN
Alzamend Neuro
3.00
Buy$180.004,516.57% Upside
Nutra Pharma Corp. stock logo
NPHC
Nutra Pharma
0.00
N/AN/AN/A
Spruce Biosciences, Inc. stock logo
SPRB
Spruce Biosciences
2.00
Hold$2.173,202.85% Upside
Windtree Therapeutics, Inc. stock logo
WINT
Windtree Therapeutics
2.00
Hold$350.0053,746.15% Upside

Current Analyst Ratings Breakdown

Latest NPHC, ALZN, SPRB, and WINT Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/16/2025
Spruce Biosciences, Inc. stock logo
SPRB
Spruce Biosciences
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetSector Perform ➝ Sector Perform$1.50 ➝ $0.50
3/17/2025
Alzamend Neuro, Inc. stock logo
ALZN
Alzamend Neuro
Ascendiant Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$288.00 ➝ $180.00
(Data available from 6/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Alzamend Neuro, Inc. stock logo
ALZN
Alzamend Neuro
N/AN/AN/AN/A($3.52) per shareN/A
Nutra Pharma Corp. stock logo
NPHC
Nutra Pharma
N/AN/AN/AN/AN/AN/A
Spruce Biosciences, Inc. stock logo
SPRB
Spruce Biosciences
$4.91M0.56N/AN/A$1.88 per share0.03
Windtree Therapeutics, Inc. stock logo
WINT
Windtree Therapeutics
N/AN/AN/AN/A$10.17 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Alzamend Neuro, Inc. stock logo
ALZN
Alzamend Neuro
-$9.95MN/A0.00N/AN/AN/AN/A-289.14%7/29/2025 (Estimated)
Nutra Pharma Corp. stock logo
NPHC
Nutra Pharma
N/AN/A0.00N/AN/AN/AN/AN/AN/A
Spruce Biosciences, Inc. stock logo
SPRB
Spruce Biosciences
-$47.92M-$1.32N/AN/AN/A-555.23%-62.10%-47.49%8/11/2025 (Estimated)
Windtree Therapeutics, Inc. stock logo
WINT
Windtree Therapeutics
-$20.29M-$823.47N/AN/AN/AN/A-362.76%-79.65%8/18/2025 (Estimated)

Latest NPHC, ALZN, SPRB, and WINT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/15/2025Q1 2025
Windtree Therapeutics, Inc. stock logo
WINT
Windtree Therapeutics
-$39.00-$4.63+$34.37-$4.63$2.20 millionN/A
4/15/2025Q4 2024
Spruce Biosciences, Inc. stock logo
SPRB
Spruce Biosciences
-$0.20-$0.57-$0.37-$0.57$0.50 million$0.55 million
3/10/2025Q3 2025
Alzamend Neuro, Inc. stock logo
ALZN
Alzamend Neuro
-$2.61-$1.71+$0.90-$0.19N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Alzamend Neuro, Inc. stock logo
ALZN
Alzamend Neuro
N/AN/AN/AN/AN/A
Nutra Pharma Corp. stock logo
NPHC
Nutra Pharma
N/AN/AN/AN/AN/A
Spruce Biosciences, Inc. stock logo
SPRB
Spruce Biosciences
N/AN/AN/AN/AN/A
Windtree Therapeutics, Inc. stock logo
WINT
Windtree Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Alzamend Neuro, Inc. stock logo
ALZN
Alzamend Neuro
N/A
3.80
3.80
Nutra Pharma Corp. stock logo
NPHC
Nutra Pharma
N/AN/AN/A
Spruce Biosciences, Inc. stock logo
SPRB
Spruce Biosciences
0.01
5.36
5.36
Windtree Therapeutics, Inc. stock logo
WINT
Windtree Therapeutics
N/A
0.27
0.27

Institutional Ownership

CompanyInstitutional Ownership
Alzamend Neuro, Inc. stock logo
ALZN
Alzamend Neuro
49.61%
Nutra Pharma Corp. stock logo
NPHC
Nutra Pharma
N/A
Spruce Biosciences, Inc. stock logo
SPRB
Spruce Biosciences
91.71%
Windtree Therapeutics, Inc. stock logo
WINT
Windtree Therapeutics
29.33%

Insider Ownership

CompanyInsider Ownership
Alzamend Neuro, Inc. stock logo
ALZN
Alzamend Neuro
30.21%
Nutra Pharma Corp. stock logo
NPHC
Nutra Pharma
61.50%
Spruce Biosciences, Inc. stock logo
SPRB
Spruce Biosciences
6.90%
Windtree Therapeutics, Inc. stock logo
WINT
Windtree Therapeutics
0.33%
CompanyEmployeesShares OutstandingFree FloatOptionable
Alzamend Neuro, Inc. stock logo
ALZN
Alzamend Neuro
4801,0004.86 millionNo Data
Nutra Pharma Corp. stock logo
NPHC
Nutra Pharma
47.10 billion2.73 billionNot Optionable
Spruce Biosciences, Inc. stock logo
SPRB
Spruce Biosciences
2042.23 million37.54 millionOptionable
Windtree Therapeutics, Inc. stock logo
WINT
Windtree Therapeutics
303.66 million11.01 millionNot Optionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Alzamend Neuro stock logo

Alzamend Neuro NASDAQ:ALZN

$3.90 -0.07 (-1.79%)
As of 02:34 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.

Nutra Pharma stock logo

Nutra Pharma OTCMKTS:NPHC

Nutra Pharma Corp., a biopharmaceutical company, acquires, licenses, and commercializes pharmaceutical products and technologies, and homeopathic and ethical drugs for the management of pain, neurological disorders, cancer, and autoimmune and infectious diseases primarily in the United States. The company offers Nyloxin and Nyloxin Extra Strength products, which are used as an oral spray for treating lower back pain, migraines, neck aches, shoulder pain, cramps, and neuropathic pain, as well as a topical gel for treating joint pain, and pain associated with arthritis and repetitive stress; Pet Pain-Away, a homeopathic, nonnarcotic, nonaddictive, and overthecounter pain reliever to treat chronic pain in companion animals; Luxury Feet, an over-the-counter pain reliever and antiinflammatory product to treat pain or discomfort due to high heels and stilettos; Nyloxin Military Strength for treating pain to the United States Military and Veteran's Administration; and Equine Pain-Away, an over-the-counter topical pain reliever to relieve pain in horses. It is also involved in developing RPI-78M to treat neurological diseases and autoimmune diseases, including multiple sclerosis, adrenomyeloneuropathy, amyotrophic lateral sclerosis, rheumatoid arthritis, and myasthenia gravis; RPI-MN to treat viral diseases comprising human immunodeficiency virus/AIDS and herpes, as well as for general anti-viral applications; RPI-78 for pain and arthritis; and RPI-70 for pain. The company was incorporated in 2000 and is based in Plantation, Florida.

Spruce Biosciences stock logo

Spruce Biosciences NASDAQ:SPRB

$0.07 +0.01 (+8.97%)
As of 02:08 PM Eastern

Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. Spruce Biosciences, Inc. has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses; and collaboration and license agreement with Kaken Pharmaceutical Co. Ltd. to develop, manufacture, and commercialize tildacerfont for the treatment of CAH in Japan. The company was incorporated in 2014 and is headquartered in South San Francisco, California.

Windtree Therapeutics stock logo

Windtree Therapeutics NASDAQ:WINT

$0.65 -0.02 (-2.29%)
As of 02:34 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Windtree Therapeutics, Inc., a biotechnology company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. The company's lead product candidate is istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as for the treatment of early cardiogenic shock. It also develops AEROSURF, an aerosolized KL4 surfactant that is in Phase 2b clinical trial to treat respiratory distress syndrome in premature infants; Surfaxin, a lyophilized KL4 surfactant, which is in Phase 2a clinical trial for the treatment of lung injury resulting from COVID-19; Rostafuroxin that is in Phase 2b clinical trial for the treatment of genetically associated hypertension; and oral and intravenous SERCA2a activator, which is in preclinical trial for the treatment of chronic and acute heart failure. In addition, it is developing aPKCi Inhibitor for the treatment of cutaneous malignancies and solid tumors that is in preclinical trials. Windtree Therapeutics, Inc. has a collaboration with Universita degli Studi di Milano-Bicocca for the discovery and development of new SERCA2a compounds for the treatment of chronic and acute human heart failure; a strategic alliance with Laboratorios del Dr. Esteve, S.A. for the development, marketing, and sale of a portfolio of potential KL4 surfactant products; license, development and commercialization agreement with Lee's Pharmaceutical (HK) Ltd. and Zhaoke Pharmaceutical (Hefei) Co. Ltd.; license agreement with Philip Morris USA, Inc. and Johnson & Johnson; and collaboration with Battelle Memorial Institute for development of its ADS for use in its phase III program. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. The company was founded in 1992 and is headquartered in Warrington, Pennsylvania.